NervGen Pharma Announces Clinical Development Plan For the Treatment of Nerve Damage and Neurodegenerative Diseases / NervGen Reports Results of Annual General Meeting of Shareholders

Vancouver, Canada. September 6, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the clinical development strategy for its compound, NVG-291, in two lead indications: spinal cord injury and multiple sclerosis. […]

NervGen Pharma’s Multiple Sclerosis Development Program Targeting Nerve Remylenation Supported by Publication of Independent Peer Reviewed Paper

Vancouver, Canada. July 10, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reports the publication of a new, independent study using NervGen’s core Intracellular Sigma Peptide (“ISP”) technology in a mouse […]

NervGen Grants Stock Option Shares for Investor Relations Consulting Services

Vancouver, Canada. July 5, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the Company granted an aggregate of 50,000 shares of stock options as part of an agreement for investor […]

NervGen Amends Investor Relations Agreement

Vancouver, Canada. July 5, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the Company has agreed to amend the terms of an investor relations services agreement dated January 16, 2019 […]

NervGen Pharma Launches Multiple Sclerosis Program Targeting Nerve Remyelination / Lead Indication for Spinal Cord Injury Continues to Advance to Phase One Clinical Trial

Vancouver, Canada. June 26, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced its goal to apply its proprietary platform drug technology beyond spinal cord injury to multiple sclerosis (“MS”), another […]

NervGen Pharma Announces Upgrade to the OTCQX® Best Market in the U.S.

Vancouver, Canada. June 10, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has qualified to trade its common shares on the OTCQX® Best Market (“OTCQX”). NervGen upgraded […]

NervGen Pharma Presenting at the 9th Annual LD Micro Invitational

Vancouver, Canada. June 4, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that Ernest Wong, NervGen Pharma’s President & CEO, will be presenting at the 9th […]

NervGen Pharma Engages Torrey Hills Capital for Investor Relations

Vancouver, Canada. June 3, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has engaged San Diego based Torrey Hills Capital, Inc. (“Torrey Hills Capital”) […]

NervGen Pharma Appoints Dr. Denis Bosc as Vice President of Manufacturing / Paul Brennan Joins NervGen Pharma as Business Advisor

Vancouver, Canada. May 30, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has appointed Denis Bosc, PhD, as the Company’s Vice President, Chemistry, Manufacturing […]

NervGen Pharma Commences Trading on OTCQB / NervGen Pharma Engages Market Maker

Vancouver, Canada. May 3, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage including spinal cord and peripheral nerve injury, today announced that in addition to trading on the TSX Venture Exchange, its common shares will […]

NervGen Pharma’s Patent Estate Grows with the Addition of US Patents for its Groundbreaking Nerve Regeneration Technology

Vancouver, B.C. April 24, 2019 NervGen Pharma Corp. (“NervGen”) (TSX.V: NGEN), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, announces the issuance by the U.S. Patent and Trademark Office of two new patents protecting the development and commercialization of protein tyrosine phosphatase sigma (PTPs) targeted therapies for heart […]

NervGen Pharma Increases Private Placement to $650,000

Vancouver, Canada. April 22, 2019 – NervGen Pharma Corp. (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has increased the amount of its non-brokered private placement announced on March 14, 2019 from $500,000 to $650,000.  The Company now intends to […]

NervGen Pharma Appoints Amy Franke as VP, Clinical Operations

Vancouver, Canada. April 1, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Amy Franke as the Company’s Vice President, Clinical Operations. “With the recent successful completion of our Initial Public Offering, we […]

NervGen Pharma Completes $10 Million Initial Public Offering / Shares to Commence Trading on TSX-V on March 15, 2019 – Symbol “NGEN”

Vancouver, Canada. March 13, 2019 – NervGen Pharma Corp. (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has completed its initial public offering (“IPO”) of its common shares and listing as a Tier 2 company on the TSX Venture Exchange […]

NervGen Pharma Appoints Dr. Michael Abrams to Board of Directors

Vancouver, Canada. September 25, 2018 – NervGen Pharma Corp. (“NervGen”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Dr. Michael J. Abrams, PhD, to the Company’s Board of Directors. Dr. Abrams brings to NervGen extensive expertise and successes gained during his over thirty-year […]

NervGen Pharma Announces Granting of US Patent for Breakthrough Nerve Regeneration Technology

Vancouver, B.C.  August 10, 2018 NervGen Pharma Corp. (“NervGen”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage,  announces the issuance by the U.S. Patent and Trademark Office of a patent central to the development and commercialization of protein tyrosine phosphatase sigma (PTPs) targeted therapies for spinal cord injury […]

NervGen Pharma Licenses Breakthrough Nerve Regeneration Technology from Case Western Reserve University

July 17, 2018—NervGen Pharma Corp. (“NervGen”), in Vancouver, and Case Western Reserve University (“Case Western Reserve”) in Cleveland have entered into an exclusive worldwide licensing agreement to research, develop and commercialize a patented technology with potential to bring new therapies for spinal cord injury and other conditions associated with nerve damage. The technology was developed […]

NervGen Pharma Appoints Dr. Ernest Wong as President & CEO

Experienced Biotechnology Executive to Lead Innovative Regenerative Medicine Company Dedicated to Creating Solutions for the Treatment of Nerve Damage Vancouver, Canada. June 21, 2018 – NervGen Pharma Corp. (“NervGen”), a private regenerative medicine company dedicated to the advancement of innovative therapeutics for the treatment of spinal cord injury and nerve damage, today announced the appointment […]